{"id":6884,"date":"2019-05-11T09:43:00","date_gmt":"2019-05-11T09:43:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=6884"},"modified":"2024-05-02T11:02:31","modified_gmt":"2024-05-02T09:02:31","slug":"su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/","title":{"rendered":"Su1934-Safety of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease undergoing concomitant treatment with immunosuppressant medications: a multicenter cohort study"},"content":{"rendered":"
\n

Maki Miyakawa, Hiroki Tanaka, Tomoyoshi Shibuya,Taro Osada, Eiji Hosoi Gastroenterol. 2019 156 (6) Suppl.S-666\u2013S-667<\/p>\n<\/div>\n\n

\n

Background: <\/strong>Few studies have assessed the safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease (IBD) undergoing concomitant treatment with multiple immunosuppressant medications. To address this research gap, we investigated adverse effects associated with GMA in patients with IBD treated with multiple immunosuppressants \u00a0who \u00a0participated \u00a0in \u00a0the \u00a0\u201cP<\/u><\/strong>ost-marketing \u00a0surveillance \u00a0study \u00a0on \u00a0the safety a<\/u><\/strong>nd r<\/strong>esponse of GMA t<\/strong>reatment i<\/strong>n patients with C<\/u><\/strong>rohn’s disease or u<\/u>l<\/strong>cerative colitis with a<\/u><\/strong>t least one special situation who r<\/strong>eceived Adacolumn\u00ae (PARTICULAR).\u201d Methods: <\/strong>The PARTICULAR study was a retrospective, multicenter cohort study of patients with ulcerative colitis (UC) or Crohn’s disease (CD) who received GMA between November 2013 and March 2017. Patients meeting at least one of the following special situation were enrolled: elderly (<=65 years) or pediatric\/adolescent (>=18 years) patients, patients with anemia, or patients undergoing concomitant treatment with multiple immunosuppressants. GMA was performed using Adacolumn\u00ae (JIMRO, Takasaki, Japan). Each patient received up to 11 GMA sessions, and all adverse events (AEs) during the study period were recorded. The incidence of AEs was investigated relative to the number and type of immunosuppressants using univariate and multivariate logistic regression analyses. Results: <\/strong>A total of 437 patients (368 UC, 69 CD) from 93 institutions were included. Of these, 140, 169, 101, and 27 patients received none, 1, 2, and >=3 immunosuppressants, respectively. In total, 125 patients received multiple immunosuppressants. Concomitant prednisolone, immunomodulators, anti-tumor necrosis factor agents, and calcineurin inhibitors were administered in 189, 151, 89, and 24 patients, respectively. The incidence of AEs was 11% in all 437 patients and 8%, 12%, 12%, and 26% in patients receiving none, 1, 2, and >=3 immunosuppressants, respectively. In multivariate logistic regression analysis, anemia and concomitant immunosuppressants were independently associated with the incidence of AEs. Particularly, a higher number of concomitant immunosuppressants showed an increasing trend with odds ratios related to AEs. In contrast, concomitant corticosteroids were associated with a reduced risk of AEs. Nausea\/vomiting and headache were the most common AEs in patients on multiple immunosuppressant medications (5.6% and 3.2%, respectively). Conclusions: <\/strong>Concomitant treatment with immunosuppressants was independently associated with the incidence of AEs such as nausea\/vomiting and headache in patients with IBD receiving GMA. As the number of concomitant immunosuppressants increased, the incidence of AEs also increased. However, our data also suggest that GMA is safe in patients with IBD receiving prednisolone.<\/p>\n<\/div>\n\n

\n

https:\/\/www.gastrojournal.org\/action\/doSearch?text1=granulocyte+and+monocyte+apheresis+&field1=AllField&AfterYear=2018&BeforeYear=2021&pageSize=50&startPage=&SeriesKey=ygast<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Maki Miyakawa, Hiroki Tanaka, Tomoyoshi Shibuya,Taro Osada, Eiji Hosoi Gastroenterol. 2019 156 (6) Suppl.S-666\u2013S-667 Background: Few studies have assessed the safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease (IBD) undergoing concomitant treatment with multiple immunosuppressant medications. To address this research gap, we investigated adverse effects associated with GMA in […]<\/p>\n","protected":false},"template":"","scientific_tags":[92,533,346,303,424,426,133,100,156,527,271],"class_list":["post-6884","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-anti-tnf","scientific_tags-calcineurin-inhibitor","scientific_tags-cohort","scientific_tags-combination","scientific_tags-gma","scientific_tags-ibd","scientific_tags-immunosuppressants","scientific_tags-multicenter","scientific_tags-safety","scientific_tags-steroid","scientific_tags-study"],"acf":{"sc_authors":"https:\/\/www.gastrojournal.org<\/a>"},"yoast_head":"\nSu1934-Safety of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease undergoing concomitant treatment with immunosuppressant medications: a multicenter cohort study - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Su1934-Safety of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease undergoing concomitant treatment with immunosuppressant medications: a multicenter cohort study - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Maki Miyakawa, Hiroki Tanaka, Tomoyoshi Shibuya,Taro Osada, Eiji Hosoi Gastroenterol. 2019 156 (6) Suppl.S-666\u2013S-667 Background: Few studies have assessed the safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease (IBD) undergoing concomitant treatment with multiple immunosuppressant medications. To address this research gap, we investigated adverse effects associated with GMA in […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T09:02:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/\",\"name\":\"Su1934-Safety of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease undergoing concomitant treatment with immunosuppressant medications: a multicenter cohort study - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2019-05-11T09:43:00+00:00\",\"dateModified\":\"2024-05-02T09:02:31+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Su1934-Safety of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease undergoing concomitant treatment with immunosuppressant medications: a multicenter cohort study - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/","og_locale":"es_ES","og_type":"article","og_title":"Su1934-Safety of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease undergoing concomitant treatment with immunosuppressant medications: a multicenter cohort study - Adacyte","og_description":"Maki Miyakawa, Hiroki Tanaka, Tomoyoshi Shibuya,Taro Osada, Eiji Hosoi Gastroenterol. 2019 156 (6) Suppl.S-666\u2013S-667 Background: Few studies have assessed the safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease (IBD) undergoing concomitant treatment with multiple immunosuppressant medications. To address this research gap, we investigated adverse effects associated with GMA in […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T09:02:31+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/","name":"Su1934-Safety of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease undergoing concomitant treatment with immunosuppressant medications: a multicenter cohort study - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2019-05-11T09:43:00+00:00","dateModified":"2024-05-02T09:02:31+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/su1934-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-inflammatory-bowel-disease-undergoing-concomitant-treatment-with-immunosuppressant-medications-a-multicenter-cohort-stu\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/6884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=6884"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=6884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}